Cancer diagnoses diminishes adherence to diabetes medications
the ONA take:
According to a new study published in the journal Diabetologia, patients with diabetes become less adherent to their antihyperglycemic medications after receiving a cancer diagnosis.
For the study, researchers sought to evaluate changes in adherence to antihyperglycemic medications used to treat diabetes after a diagnosis of cancer. Researchers identified 52,228 antihyperglycemic mediation users from the Eindhoven Cancer Registry-PHARMO Database Network in the Netherlands between 1998 and 2011. Of those, they identified 3,281 cases with cancer and 12,891 controls without cancer.
Results showed that before a cancer diagnosis, the medication possession ratio (MPR), an indicator for medication adherence, was increased by 0.10% per month. At the time of cancer diagnosis, researchers found that the MPR decreased by 6.3%, which continued to decline by 0.20% monthly thereafter.
Patients diagnosed with stage 4 cancer and those with gastroinestinal or pulmonary cancers had the largest declines in MPR. The initial 6% MPR decrease translates to a patient missing 2 days of their antihyperglycemic medications.
The findings suggest that a cancer diagnosis can diminish adherence to medications of patients' other chronic conditions.
Patients with diabetes become less adherent to their antihyperglycemic medications after receiving a cancer diagnosis.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|